Table 2.

Evaluation of diagnostic and therapeutic characteristics and modalities in patient management; md—mediana; IQR—interquartile range; HCC—hepatocellular carcinoma; RFA—radiofrequency ablation; TACE—trans-arterial chemoembolization.

Variable		N = 216
HCV RNA quantitative testing, median (IQR)	523,500.0 (18,310.0–2,235,400.0)
Sustained virologic response, n (%)	at post-treatment Week 4	212 (98.1)
	at post-treatment Week 12	211 (97.7)
Hepatitis C genotype, n (%)	1a	79 (36.5)
	1b	39 (18.1)
	2	5 (2.3)
	3	73 (33.8)
	4	20 (9.3)
Antiviral therapy, n (%)	Glecaprevir/pibrentasvir	118 (54.6)
	Elbasvir/grazoprevir	30 (13.9)
	Sofosbuvir/velpatasvir +/− ribavirin	68 (36.0)
Method of liver fibrosis assessment, n (%)	Fibrosis-4 (FIB-4) index	61 (28.2)
	Liver stiffness measurement	127 (58.8)
	Liver biopsy	28 (13.0)
Fibrosis stage, n (%)	F0/1	113 (52.3)
	F2	34 (15.8)
	F3	16 (7.4)
	F4	53 (24,5)
Liver stiffness measurement	F0/1, n (%)	74 (34.3)
	F2, n (%)	21 (9.7)
	F3, n (%)	6 (2.8)
	F4, n (%)	17 (7.9)
	Fibrosis stage kPa, md (IQR)	6.5 (5.0–9.2)
	Steatosis S0, n (%)	69 (31.9)
	Steatosis S1, n (%)	26 (12.0)
	Steatosis S2/3, n (%)	19 (8.8)
	Degree of steatosis dB/m, md (IQR)	215.6 (190.1–242.5)
Fibrosis-4 index, n (%)	F0/1	34 (15.8)
	F2/3	10 (4.6)
	F3/4	26 (12.0)
Liver cirrhosis and Child–Pugh classification	Total cirrhotic patients	50 (23.1)
	Class A	39 (18.0)
	Class B	10 (4.6)
	Class C	1 (0.5)
Complications of liver cirrhosis	Ascites, n (%)	12 (5.5)
	Hepatic encephalopathy, n (%)	5 (2.3)
	Portal hypertension, n (%)	22 (10.1)
	Esophageal varices, n (%)	20 (9.3)
Hepatocellular carcinoma and treatment modalities, n (%)	Total HCC patients	10 (4.2)
	Surgical resection	5 (2.3)
	RFA/TACE	3 (1.4)
	Palliative care	2 (0.9)